Bridging the gap between the north and south of the world: The case of treatment response in childhood acute lymphoblastic leukemia

Haematologica

Volumn 94, Issue 6, 2009, Pages 748-752

  Stanulla, Martin ^a   Schrauder, André ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL FEATURE; HUMAN; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; PROGNOSIS; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTIGENS, CD19; ANTIGENS, CD34; CHILD; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMANS; LEUKEMIA, B-CELL; NEOPLASM, RESIDUAL; NEPRILYSIN; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL;

EID: 66749109294     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.006783     Document Type: Review

References (27)

1. Pui CH, Evans WE. Treatment of childhood acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178 (Pubitemid 43076714)
2. Tucci F, Arico M. Treatment of pediatric acute lymphoblastic leukaemia. Haematologica 2008;93:1124-1128
3. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, et al. Die Corticosteroidabhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83). [The in vivo response on corticosteroid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83)]. Klin Pädiatr 1987;199:151-160 (Pubitemid 17079852)
4. Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 1996;14:2403-2406
5. Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997;80:1717-1726 (Pubitemid 27475928)
6. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman P, Miller DR, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990;18:273-279 (Pubitemid 20219917)
7. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the Children's Cancer Group. J Clin Oncol 1996;14:389-398 (Pubitemid 26050999)
8. Lauten M, Stanulla M, Zimmermann M, Welte K, Riehm H, Schrappe M. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Padiatr 2001;213:169-174 (Pubitemid 32801568)
9. van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-1738 (Pubitemid 28534955)
10. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998;339:591-598
11. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998;351:550-554 (Pubitemid 28077560)
12. Dworzak MN, Fröschl G, Printz D, Mann G, Pötschger U, Mühlegger N, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99: 1952-1958 (Pubitemid 34525474)
13. Cazzaniga G, Rossi V, Biondi A. Monitoring minimal residual disease using chromosomal translocations in childhood. Best Pract Res Clin Haematol 2002;15:21-35. (Pubitemid 34285181)
14. Ciudad J, San Miguel JF, López-Berges MC, Vidriales B, Valverde B, Ocqueteau M, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998;16:3774-3781 (Pubitemid 29001529)
15. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691-2696
16. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604-611 (Pubitemid 46444541)
17. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-2357
18. Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible. Cytometry B Clin Cytom 2008;74:331-340
19. Irving J, Jesson J, Virgo P, Case M, Minto L, Eyre L, et al. on behalf of the UKALL Flow MRD group and UK MRD steering group. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica 2009; 94:870-874
20. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, et al. Riskadjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477-4489
21. Arico M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E, et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer 1995;75:1684-1693
22. Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995;86:1292-1295
23. Kaspers GJ, Pieters R, Van Zantwijk CH, van Wering ER, van der Does-van den Berg A, Veerman AJP. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitrovivo correlations and cross-resistance to other drugs. Blood 1998;92:259-266 (Pubitemid 28303201)
24. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOPBFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008;22:771-782
25. Scrideli CA, Assumpção JG, Ganazza MA, Araújo M, Toledo SR, Lee MLM, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica 2009;94:781-789
26. Coustan-Smith E, Ribeiro RC, Stow P, Zhou Y, Pui CH, Rivera GK, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006;108:97-102. (Pubitemid 43990616)
27. Campana D. Molecular determinants of treatment response in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2008;366-373